# US 2022/0033489 A1 · Methods and compositions for treating asthma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033489 A1
- Document ID: US20220033489A1
- Status: Published application
- Kind: A1
- Application number: 17/299,664
- Filed: 2019-12-04
- Published: 2022-02-03
- Earliest claimed: 2018-12-04
- Assignees: Children's Medical Center Corporation
- Applicants: The Children's Medical Center Corporation
- Inventors: Talal Amine CHATILA; Hani HARB; Brittany ESTY; Wanda PHIPATANAKUL; Lisa M. BARTNIKAS
- Web page: https://patentgrep.com/patent/US20220033489A1

## CPC

- C07K 16/248: {IL-6}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/06: Antiasthmatics
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 2039/505: {comprising antibodies}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are methods and compositions for treating asthma. Aspects of the invention relates to administering to a subject an agent that inhibits IL-6 signaling. Another aspect of the invention relates to administering the anti-IL-6R antibody, tocilizumab, to a subject in need thereof.

## Claims

### Claim 1

1) A method of treating asthma, the method comprising administering to a subject in need thereof an effective amount of an agent that inhibits the IL-6 signaling.

### Claim 2 (depends on 1)

2) The method of claim 1, wherein the asthma is pediatric asthma.

### Claim 3 (depends on 1, 2)

3) The method of claim 1 or 2, wherein the asthma is non-atopic asthma.

### Claim 4 (depends on 1, 2, 3)

4) The method of any of claims 1-3, wherein the asthma is severe, persistent asthma.

### Claim 5 (depends on 1)

5) The method of claim 1, further comprising, prior to administration, diagnosing a subject with having asthma.

### Claim 6 (depends on 1, 2, 3, 4, 5)

6) The method of any of claims 1-5, wherein the subject has a mutation in the IL4R gene.

### Claim 7 (depends on 6)

7) The method of claim 6, wherein the subject is a homozygous for IL4R dominant allele.

### Claim 8 (depends on 6)

8) The method of claim 6, wherein the subject is a homozygous for IL4R mutant allele.

### Claim 9 (depends on 1)

9) The method of claim 1, further comprising, prior to administration, identifying a subject as having a mutation in the IL4R gene.

### Claim 10 (depends on 1)

10) The method of claim 1, further comprising, prior to administration, receiving results that identify a subject as having a mutation in the IL4R gene.

### Claim 11 (depends on 1)

11) The method of claim 1, wherein the agent that inhibits IL-6 signaling is selected from the group consisting of a small molecule, an antibody, a peptide, a genome editing system, an antisense oligonucleotide, and an RNAi.

### Claim 12 (depends on 11)

12) The method of claim 11, wherein the RNAi is a microRNA, an siRNA, or a shRNA.

### Claim 13 (depends on 11)

13) The method of claim 11, wherein the antibody is a humanized antibody.

### Claim 14 (depends on 13)

14) The method of claim 13, wherein the humanized antibody is tocilizumab.

### Claim 15 (depends on 11, 12, 13, 14)

15) The method of any of claim 11-14, wherein the agent targets IL-6 or IL-6 receptor (IL-6R).

### Claim 16 (depends on 1)

16) The method of any of claim 1, wherein inhibiting IL-6 or TL-6R is inhibiting the expression level and/or activity of IL-6 or IL-6R.

### Claim 17 (depends on 16)

17) The method of claim 16, wherein the expression level and/or activity of IL-6 or IL-6R is inhibited by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more as compared to an appropriate control.

### Claim 18 (depends on 1)

18) The method of claim 1, wherein administration decreases circulation of a cell selected from the group consisting of: a IL-4+Foxp3+ (TH2-like) T regulatory cell, a IL-17+Foxp3+ (TH17-like) T regulatory cell, a TH2 cell, and a TH17 cell.

### Claim 19 (depends on 18)

19) The method of claim 18, wherein circulation is decreased by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more as compared to an appropriate control.

### Claim 20 (depends on 1)

20) The method of claim 1, wherein the agent is administered at a concentration of 8 mg/kg or 10 mg/kg.

### Claim 21 (depends on 1)

21) The method of claim 1, further comprising administering at least a second asthma therapeutic.

### Claim 22

22) A method of treating asthma, the method comprising administering to a subject in need thereof an effective amount of tocilizumab.

### Claim 23 (depends on 22)

23) The method of claim 22, wherein the asthma is pediatric asthma.

### Claim 24 (depends on 22, 23)

24) The method of claim 22 or 23, wherein the asthma is non-atopic asthma.

### Claim 25 (depends on 22, 23, 24)

25) The method of any of claims 22-24, wherein the asthma is severe, persistent asthma.

### Claim 26 (depends on 22)

26) The method of claim 22, further comprising, prior to administration, diagnosing a subject with having asthma.

### Claim 27 (depends on 22, 23, 24, 25, 26)

27) The method of any of claims 22-26, wherein the subject has a mutation in the TL4R gene.

### Claim 28 (depends on 27)

28) The method of claim 27, wherein the subject is a homozygous for IL4R dominant allele.

### Claim 29 (depends on 27)

29) The method of claim 27, wherein the subject is a homozygous for IL4R mutant allele.

### Claim 30 (depends on 22)

30) The method of claim 22, further comprising, prior to administration, identifying a subject as having a mutation in the TL4R gene.

### Claim 31 (depends on 22)

31) The method of claim 22, further comprising, prior to administration, receiving results that identify a subject as having a mutation in the TL4R gene.

### Claim 32 (depends on 22)

32) The method of claim 22, wherein tocilizumab is administered at a concentration of 8 mg/kg or 10 mg/kg.

### Claim 33 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

33) The method of claim any of claims 22-32, wherein tocilizumab is administered once every 2 weeks or once every 4 weeks.

### Claim 34 (depends on 22)

34) The method of claim 22, wherein administration decreases circulation of a cell selected from the group consisting of: a IL-4+Foxp3+ (TH2-like) T regulatory cell, a IL-17+Foxp3+ (TH17-like) T regulatory cell, a TH2 cell, and a TH17 cell.

### Claim 35 (depends on 34)

35) The method of claim 34, wherein circulation is decreased by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more as compared to an appropriate control.

### Claim 36 (depends on 22)

36) The method of claim 22, further comprising administering at least a second asthma therapeutic.

### Claim 37

37) A composition comprising an agent that inhibits IL-6 signaling.

### Claim 38 (depends on 37)

38) The composition of claim 37, further comprising a pharmaceutically acceptable carrier.
